Corpus ID: 2721906

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

@article{Francis1998AdvancingAT,
  title={Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.},
  author={Donald Francis and Timothy J. Gregory and M. Julie Mcelrath and Robert B Belshe and Geoffrey J Gorse and S Migasena and Dwip Kitayaporn and Punnee Pitisuttitham and Thomas J. Matthews and David H. Schwartz and Phillip W Berman},
  journal={AIDS research and human retroviruses},
  year={1998},
  volume={14 Suppl 3},
  pages={
          S325-31
        }
}
AIDSVAX (VaxGen, Inc., South San Francisco, CA), a possible vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection, is being tested for efficacy in phase 3 studies. It has been tested for potential efficacy in chimpanzees, and tested for safety and immunogenicity in human clinical studies. Four candidate vaccines, each with a different envelope protein antigen or combination of antigens, have been produced in alum formulations. In both design and clinical testing… Expand

Paper Mentions

Interventional Clinical Trial
AMENDED 11/17/93: To determine whether the pattern of response to MN rgp120 vaccine is altered by pre-exposure to IIIB rgp120. ORIGINAL DESIGN: To evaluate the safety (clinical… Expand
ConditionsHIV Infections
InterventionBiological
Interventional Clinical Trial
AMENDED 10/1/93: To evaluate the influence of prior immunization with an rgp120 vaccine on immune response to a subsequent immunization with a different strain of rgp120 (VEU 009X… Expand
ConditionsHIV Infections
InterventionBiological
Biological considerations in the development of a human immunodeficiency virus vaccine.
TLDR
It will be necessary to address a number of biological questions that underpin the rational development of an AIDS vaccine to lead to the formulation of a safe and effective AIDS vaccine. Expand
Progress on the Induction of Neutralizing Antibodies Against HIV Type 1 (HIV-1)
TLDR
The efforts made up to this point to elicit antibody responses against HIV-1 are reviewed, especially with regard to the use of a DNA prime-protein boost regimen, which has been proven to be a highly effective platform for the induction of neutralizing antibodies in both animal and early-phase human studies. Expand
18 – HIV VACCINES: MILESTONES AND NEW INSIGHTS
This chapter focuses on the reason behind the growing conviction that an HIV vaccine is possible, with many obstacles and difficulties still unresolved. Despite the extensive research that have goneExpand
New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview.
TLDR
A totally novel vaccine approach based on the use of Tat or Tat and Rev antigens has been shown to induce efficient protection from challenge with pathogenic SIV or SIV/HIV (SHIV) challenge in vaccinated macaques. Expand
HIV-1 Vaccine Testing, Trial Design, and Ethics
To minimize the time until practical and efficacious HIV-1 vaccines are widely distributed in Africa, it is important to continually conduct vaccine preparedness studies and standardized, comparativeExpand
Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.
TLDR
Weak overall neutralizing antibody responses against tier 2 viruses is consistent with a lack of protection in this trial, and should be useful for identifying improved vaccines. Expand
HIV-1 polymorphism: a challenge for vaccine development - a review.
TLDR
An updating of HIV-1 subtypes and recombinant viruses circulating in South American countries, focusing mainly on Brazil, is presented as one of the challenges for HIV vaccine development. Expand
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV
TLDR
This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition and represents the first sign that a preventive vaccine for HIV may be feasible. Expand
Rational development of prophylactic HIV vaccines based on structural and regulatory proteins.
TLDR
This review addresses the scientific problems and complications facing the development of an HIV vaccine as well as the possible strategies currently available to overcome these problems. Expand
Immunogen sequence: the fourth tier of AIDS vaccine design
TLDR
This review shall compare three computational approaches for immunogen design: the consensus sequence, which has at each site the modal nucleotide or amino acid residue across a sequence alignment; the most recent common ancestor, the sequence estimated at the basal node of the clades seen in the HIV-1 phylogeny; and the center of tree method, which minimizes the evolutionary distance to all sequences in the data set. Expand
...
1
2
3
4
5
...